We provide you with 20 years of free, institutional-grade data for FATE stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of FATE. Explore the full financial landscape of FATE stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-12 | 0001434316 | FATE | 10-Q | Url |
| 2025-05-13 | 0001434316 | FATE | 10-Q | Url |
| 2025-03-05 | 0001434316 | FATE | 10-K | Url |
| 2024-11-12 | 0001434316 | FATE | 10-Q | Url |
| 2024-08-13 | 0001434316 | FATE | 10-Q | Url |
| 2024-05-09 | 0001434316 | FATE | 10-Q | Url |
| 2024-02-26 | 0001434316 | FATE | 10-K | Url |
| 2023-11-08 | 0001434316 | FATE | 10-Q | Url |
| 2023-08-08 | 0001434316 | FATE | 10-Q | Url |
| 2023-05-03 | 0001434316 | FATE | 10-Q | Url |
| 2023-02-28 | 0001434316 | FATE | 10-K | Url |
| 2022-11-03 | 0001434316 | FATE | 10-Q | Url |
| 2022-08-03 | 0001434316 | FATE | 10-Q | Url |
| 2022-05-04 | 0001434316 | FATE | 10-Q | Url |
| 2022-02-28 | 0001434316 | FATE | 10-K | Url |
| 2021-11-04 | 0001434316 | FATE | 10-Q | Url |
| 2021-08-04 | 0001434316 | FATE | 10-Q | Url |
| 2021-05-05 | 0001434316 | FATE | 10-Q | Url |
| 2021-02-24 | 0001434316 | FATE | 10-K | Url |
| 2020-11-05 | 0001434316 | FATE | 10-Q | Url |
| 2020-08-05 | 0001434316 | FATE | 10-Q | Url |
| 2020-05-11 | 0001434316 | FATE | 10-Q | Url |
| 2020-03-02 | 0001434316 | FATE | 10-K | Url |
| 2019-11-05 | 0001434316 | FATE | 10-Q | Url |
| 2019-08-06 | 0001434316 | FATE | 10-Q | Url |
| 2019-05-07 | 0001434316 | FATE | 10-Q | Url |
| 2019-03-05 | 0001434316 | FATE | 10-K | Url |
| 2018-11-01 | 0001434316 | FATE | 10-Q | Url |
| 2018-08-06 | 0001434316 | FATE | 10-Q | Url |
| 2018-05-10 | 0001434316 | FATE | 10-Q | Url |
| 2018-03-05 | 0001434316 | FATE | 10-K | Url |
| 2017-11-01 | 0001434316 | FATE | 10-Q | Url |
| 2017-08-14 | 0001434316 | FATE | 10-Q | Url |
| 2017-05-15 | 0001434316 | FATE | 10-Q | Url |
| 2017-03-16 | 0001434316 | FATE | 10-K | Url |
| 2016-11-07 | 0001434316 | FATE | 10-Q | Url |
| 2016-08-08 | 0001434316 | FATE | 10-Q | Url |
| 2016-05-09 | 0001434316 | FATE | 10-Q | Url |
| 2016-03-03 | 0001434316 | FATE | 10-K | Url |
| 2015-11-03 | 0001434316 | FATE | 10-Q | Url |
| 2015-08-05 | 0001434316 | FATE | 10-Q | Url |
| 2015-05-07 | 0001434316 | FATE | 10-Q | Url |
| 2015-03-12 | 0001434316 | FATE | 10-K | Url |
| 2014-11-12 | 0001434316 | FATE | 10-Q | Url |
| 2014-08-12 | 0001434316 | FATE | 10-Q | Url |
| 2014-05-13 | 0001434316 | FATE | 10-Q | Url |
| 2014-03-17 | 0001434316 | FATE | 10-K | Url |
| 2013-11-13 | 0001434316 | FATE | 10-Q | Url |
| 2013-08-14 | 0001434316 | FATE | S-1 | Url |
Fate Therapeutics, Inc(NASDAQ:FATE) 
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, ...
Website: http://www.fatetherapeutics.com
Founded: 2007
Full Time Employees: 178
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about FATE stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.